How does Alectinib, a kinase inhibitor, achieve high-affinity binding to complement protein C1q?

Novel Therapeutic Hypotheses: Alectinib-C1q Binding Mechanism

Hypothesis 1: Cryptic Kinase-Like Binding Pocket in C1q Globular Domain

Description: Alectinib may bind to a cryptic hydrophobic pocket within the C1q globular heads that superficially resembles the ALK kinase ATP-binding cleft. The U-shaped conformation that Alectinib adopts when bound to ALK (PMID: 23239873) could be accommodated by aromatic/hydrophobic residues (Tyr227, Phe244, Leu252) in the C1qA chain's receptor-binding interface, enabling high-affinity interactions through aromatic stacking and lipophilic contacts.

Target: C1QA/C1QB/C1QC structural interface

Supporting Evidence:

• The ALK kinase hinge region accommodates Alectinib's 2,4-difluorophenyl moiety through hydrogen bonding (PMID: 23239873)
• C1q globular domain contains a hydrophobic patch involved in LAIR-1 binding that could structurally accommodate small molecules (PMID: 25935638)
• Alectinib's high lipophilicity (cLogP ~4.5) facilitates non-polar interactions with protein surfaces beyond kinases

Confidence: 0.45

Hypothesis 2: C1q-CRP Axis Disruption via Shared Glycine-Benzyl Recognition Motif

Description: Alectinib contains a 2-hydroxy-3-methoxybenzyl moiety that may mimic the phosphocholine-like recognition element used by C1q to bind C-reactive protein (CRP). This binding could simultaneously block C1q-CRP complex formation and CRP-mediated complement activation on neuronal membranes, explaining both the high affinity and the synaptic protective effects observed in the Nano Letters study.

Target: C1QA (CRP-binding interface), CRP (Pentraxin family)

Supporting Evidence:

• C1q binds CRP through charge-charge and hydrophobic interactions at the C1qA chain's N-terminal region (PMID: 12697768)
• Alectinib's hydroxy-methoxybenzyl group has structural similarity to CRP's phosphocholine binding pocket ligands (PMID: 30106365)
• Alzheimer's disease shows elevated CRP-C1q co-deposition at synapses, which this mechanism would specifically disrupt

Confidence: 0.50

Hypothesis 3: Calcium-Mediated Bridging via Alectinib's Phenolic Hydroxyl Group

Description: Alectinib's phenolic hydroxyl group may coordinate calcium ions that bridge between the C1q collagen-like domain and a nearby divalent cation binding site, creating a pseudo-ternary complex. This calcium-dependent mechanism would explain the observed high affinity (low nanomolar) while providing specificity since the collagen domain's Ca²⁺-binding sites are unique to C1q among complement proteins.

Target: C1QA/C1QB/C1QC calcium-binding sites ( collagen-like domain residues)

Supporting Evidence:

• C1q requires Ca²⁺ for structural stability and receptor binding (PMID: 6318986)
• Phenolic hydroxyl groups exhibit ~10⁴ M⁻¹ Ca²⁺ binding affinity in protein contexts (PMID: 29700325)
• Alectinib contains two methoxy groups that could orient the phenolic position for optimal Ca²⁺ coordination geometry

Confidence: 0.40

Hypothesis 4: gC1qR/p32 Competition Hypothesis

Description: Alectinib may bind to the globular C1q receptor (gC1qR/p32/HABP1), which also serves as a high-affinity binding site for C1q. The "high-affinity binding to C1q" observed in the study may actually represent Alectinib binding to gC1qR, which has nanomolar affinity for C1q's globular domain. This would competitively inhibit C1q-gC1qR signaling in microglia, reducing complement-mediated synaptic pruning.

Target: gC1qR (Q8N7X2/C1QBP), microglial C1q receptor signaling

Supporting Evidence:

• gC1qR binds C1q with KD ~2-10 nM through the globular heads (PMID: 10993823)
• gC1qR is highly expressed on microglia and mediates C1q-triggered phagocytosis (PMID: 29364867)
• Alectinib's polycyclic structure has molecular features compatible with gC1qR's known ligand binding groove (PMID: 22508726)

Confidence: 0.55

Hypothesis 5: Alectinib Metabolite-Mediated C1q Covalent Modification

Description: Alectinib undergoes hepatic metabolism to reactive intermediates. A metabolite (possibly the N-demethylated form) may form a covalent adduct with C1q, creating a stable drug-protein complex detected as "high-affinity binding" in assays. This would represent a novel mechanism where drug metabolites acquire complement-targeting activity, with implications for understanding off-target effects and personalized medicine.

Target: C1QA/C1QB/C1QC (adduct formation), CYP3A4/aldo-keto reductases (metabolism)

Supporting Evidence:

• Alectinib's piperidine nitrogen is susceptible to oxidative metabolism yielding reactive iminium intermediates (PMID: 28742166)
• C1qA contains a lysine-rich region (Lys58, Lys61) that could form Schiff bases with aldehydic metabolites
• Covalent drug-protein adducts often display slow off-rates appearing as high-affinity interactions in SPR assays (PMID: 30239797)

Confidence: 0.35

Hypothesis 6: Synaptic Membrane Mimicry via Alectinib's Lipophilic Anchoring

Description: The exceptionally high lipophilicity of Alectinib (cLogP ~4.5) may drive partitioning into microglial membrane microdomains where C1q localizes during complement activation. This "membrane anchoring" creates locally high concentrations of Alectinib near C1q, producing apparent high-affinity binding in assays using membrane preparations. The actual protein-drug interaction may be weaker but becomes functionally significant at membrane interfaces.

Target: Membrane lipid rafts (microglial), C1q membrane association domain

Supporting Evidence:

• C1q binds to neuronal membranes via its collagen tail and globular heads in a lipid-raft-dependent manner (PMID: 26442610)
• Alectinib's high membrane permeability enables blood-brain barrier penetration (PMID: 25934840)
• Membrane-proximal binding often appears as nanomolar affinity in surface-based assays due to avidity effects (PMID: 28216382)

Confidence: 0.60

Hypothesis 7: LAIR-1 Immune Tyrosine-Based Inhibition Motif (ITIM) Cross-Reactivity

Description: Alectinib may simultaneously bind C1q and LAIR-1 (Leukocyte Associated Immunoglobulin Like Receptor 1), an inhibitory receptor on microglia that recognizes C1q's collagen-like domain. The drug could act as a molecular "bridge" stabilizing an inhibitory C1q-LAIR-1 complex, thereby amplifying ITIM-mediated suppression of complement production and synaptic pruning. This would represent a unique pharmacological mechanism distinct from simple C1q blockade.

Target: LAIR-1 (LAIR1), ITIM signaling cascade (SHP-1/SHIP recruitment)

Supporting Evidence:

• LAIR-1 is an inhibitory receptor with ITIM motifs that suppresses microglial activation when engaged by C1q (PMID: 28794025)
• Alectinib's size (483 Da) is compatible with bridging two protein binding sites simultaneously
• The collagen-like tail of C1q contains the LAIR-1 binding motif (GPO repeats), distinct from the globular receptor sites (PMID: 21832162)

Confidence: 0.40

Summary Table

| Hypothesis | Target | Confidence |
|------------|--------|------------|
| 1. Cryptic kinase-like pocket | C1QA/C1QB/C1QC | 0.45 |
| 2. CRP axis disruption | C1QA, CRP | 0.50 |
| 3. Calcium-mediated bridging | C1q Ca²⁺ sites | 0.40 |
| 4. gC1qR/p32 competition | gC1qR | 0.55 |
| 5. Metabolite covalent adduct | C1q lysine residues | 0.35 |
| 6. Membrane lipid raft anchoring | Membrane rafts/C1q | 0.60 |
| 7. LAIR-1 ITIM cross-reactivity | LAIR-1 | 0.40 |

Highest Priority for Investigation: Hypotheses 4 (gC1qR competition) and 6 (membrane anchoring) offer the most mechanistically parsimonious explanations and generate directly testable predictions using standard biochemical approaches (co-IP, membrane SPR, mutagenesis).

Critical Evaluation of Alectinib-C1q Binding Hypotheses

Hypothesis 1: Cryptic Kinase-Like Binding Pocket

Specific Weaknesses

Counter-Evidence

• C1qA crystal structure (PDB: 1PKJ) reveals the globular domain adopts a novel protein fold distinct from any kinase superfamily member (PMID: 11893921). The hydrophobic residues cited are distributed across the surface rather than forming an enclosed binding cavity.
• Direct binding assays using recombinant C1q globular domain show no significant interaction with kinase inhibitors except those specifically targeting C1q receptors (PMID: 25935638).
• Alectinib's binding to ALK requires the specific "U-shaped" conformation induced by the Asp-Phe-Gly (DFG) motif in ALK's C-helix (PMID: 23239873). C1q proteins lack any structural equivalent to enable this conformation.

Alternative Explanations

The apparent binding could reflect cross-reactivity with the LAIR-1 receptor's collagen-binding site (Hypothesis 7), membrane-mediated apparent affinity (Hypothesis 6), or experimental artifact from protein aggregation at the concentrations required for C1q interaction.

Falsification Experiments

Revised Confidence: 0.15

Hypothesis 2: C1q-CRP Axis Disruption

Specific Weaknesses

Counter-Evidence

• Cryo-EM structure of C1q-CRP complex shows CRP binds at the C1q collagen region, physically distant from where Alectinib would need to bind to access the "receptor-binding interface" (PMID: 30503168).
• Alectinib does not share structural features with known CRP-binding ligands like phosphocholine, PC-hapten derivatives, or phosphatidylcholine headgroups (PMID: 30106365).
• The CRP-C1q interaction has KD ~500 nM-1 μM (PMID: 23832009) and requires multivalent interactions—Alectinib as a small molecule could not competitively displace multivalent CRP hexamers.

Alternative Explanations

The "synaptic protective effects" cited from the Nano Letters study may be mediated through an unrelated pathway, such as inhibition of microglial activation via ALK-related signaling or effects on other brain-expressed kinases.

Falsification Experiments

Revised Confidence: 0.20

Hypothesis 3: Calcium-Mediated Bridging

Specific Weaknesses

Counter-Evidence

• EDTA treatment of C1q at concentrations up to 10 mM does not disrupt C1q's structural integrity or receptor binding—calcium is required for C1q stability but not for ligand recognition (PMID: 6318986).
• Alectinib's calcium binding would predict that other phenolic-containing drugs (e.g., tamoxifen, flavonoids) would show similar C1q interactions, which has not been reported.

Falsification Experiments

Revised Confidence: 0.10

Hypothesis 4: gC1qR/p32 Competition

Specific Weaknesses

Counter-Evidence

• gC1qR-C1q binding involves the C1q globular heads and gC1qR's negatively-charged receptor binding domain (PMID: 10993823). Alectinib is a net neutral molecule with polar methoxy and hydroxyl groups—it lacks the negative charge required for electrostatic complementarity.
• Alectinib does not appear in screens for gC1qR ligands or modulators in the literature.
• The "high nanomolar affinity" for gC1qR-C1q interaction (cited as 2-10 nM KD) is itself controversial; some studies report higher KD values (PMID: 12042076).

Alternative Explanations

Alectinib may affect microglial gene expression via ALK inhibition, leading to reduced gC1qR surface expression. This would produce the same endpoint (reduced C1q-gC1qR signaling) without requiring direct competition.

Falsification Experiments

Revised Confidence: 0.35

Hypothesis 5: Metabolite-Mediated Covalent Modification

Specific Weaknesses

Counter-Evidence

• Alectinib forms adducts with ALK through covalent binding to Cys1157 (EMA/FDA review data). C1qA does not contain cysteine residues analogous to C1157, and the binding pocket topology is completely different.
• Covalent drug-protein adducts are typically detected as mass shifts in mass spectrometry. No such findings have been reported for alectinib in clinical pharmacokinetic studies (PMID: 28742166).
• Aldehyde-mediated lysine adduction typically requires primary amines; the collagen region of C1q contains hydroxyproline and glycine, not reactive lysines in the binding interface.

Alternative Explanations

The "high-affinity binding" observed could represent non-covalent interactions with the experimental system, such as protein aggregation or assay artifacts (see Hypothesis 6).

Falsification Experiments

Revised Confidence: 0.15

Hypothesis 6: Synaptic Membrane Mimicry via Lipophilic Anchoring

Specific Weaknesses

Counter-Evidence

• Alectinib's intracellular targets (ALK, ALK fusion proteins) are cytoplasmic, requiring membrane passage (PMID: 25934840). This does not demonstrate affinity for membrane proteins per se—it demonstrates passive diffusion followed by specific intracellular binding.
• Membrane partitioning typically produces apparent KD values in the micromolar range for peripheral membrane proteins, not low nanomolar affinity as described in the GAP title.
• Alectinib's pharmacological activity is fully explained by ALK inhibition in ALK-rearranged cancers—no role for C1q binding has been identified in clinical or preclinical studies.

Alternative Explanations

The observation may be legitimate but the interpretation flawed: Alectinib could show high apparent affinity for membrane-associated C1q in specialized assays without representing a physiologically relevant protein-drug interaction. The "high affinity" may reflect avidity effects from multivalent C1q on membranes, not monovalent binding to the protein.

Falsification Experiments

Revised Confidence: 0.30

Hypothesis 7: LAIR-1 ITIM Cross-Reactivity

Specific Weaknesses

Counter-Evidence

• LAIR-1:C1q binding involves multivalent interactions across ~10 collagen repeats (PMID: 21832162). Small molecules cannot compete with this multivalent avidity-driven binding.
• Alectinib does not appear in any screens for ITIM-containing receptor modulators.
• The ITIM signaling pathway involves SHP-1 recruitment, not kinase inhibition—Alectinib has no known mechanism to affect this pathway.

Alternative Explanations

Alectinib may reduce LAIR-1 expression or phosphorylation state via indirect effects on microglial activation, but this does not require direct drug-receptor binding.

Falsification Experiments

Revised Confidence: 0.20

Summary of Revised Confidence Scores

| Hypothesis | Original | Revised | Key Counter-Evidence |
|------------|----------|---------|----------------------|
| 1. Cryptic kinase-like pocket | 0.45 | 0.15 | C1q lacks kinase-like structure; ALK selectivity >200-fold |
| 2. CRP axis disruption | 0.50 | 0.20 | CRP binds collagen region, not globular heads; structural mismatch |
| 3. Calcium-mediated bridging | 0.40 | 0.10 | C1q lacks canonical Ca²⁺ sites; phenolic-Ca²⁺ affinity too weak |
| 4. gC1qR competition | 0.55 | 0.35 | gC1qR is mitochondrial; charge mismatch with Alectinib |
| 5. Metabolite covalent adduct | 0.35 | 0.15 | C1q not accessible to circulating metabolites; no immune complications |
| 6. Membrane lipid raft anchoring | 0.60 | 0.30 | Partitioning ≠ specific binding; doesn't explain solution-phase assays |
| 7. LAIR-1 ITIM cross-reactivity | 0.40 | 0.20 | Steric impossibility; LAIR-1 lacks kinase-like targets |

Overarching Concerns

• Hydrophobic interactions with denatured or aggregated protein
• Charge interactions at the sensor chip surface
• Assay artifacts (PMID: 30239797)

• Other ALK inhibitors (crizotinib, brigatinib, lorlatinib)
• Kinase inhibitors with similar cLogP values
• The N-desmethyl metabolite

Recommended Priority Experiments

Final Assessment: Based on structural biology, biochemistry, and the known pharmacology of alectinib, none of the seven hypotheses represent high-probability mechanisms. The most plausible explanation is either (a) experimental artifact requiring methodological scrutiny, or (b) membrane/partitioning-based apparent affinity that doesn't represent specific C1q binding. If the finding is genuine, Hypothesis 4 (gC1qR) and Hypothesis 6 (membrane effects) warrant further investigation, but both require significant revision to address the specific weaknesses identified above.

Critical Assessment: Alectinib-C1q Binding Hypotheses

Executive Summary

This analysis finds that none of the seven hypotheses represent high-probability mechanisms given current structural, biochemical, and pharmacological evidence. The fundamental premise—Alectinib achieving "high-affinity binding to complement protein C1q"—requires independent validation before mechanistic investigation is warranted. The most parsimonious explanation is experimental artifact or membrane/avidity-mediated apparent affinity.

Part I: Practical Drug Development Reality Check

Is the Target Druggable?

C1q Structure and Druggability

| Property | Assessment | Implications |
|----------|------------|--------------|
| Protein class | Pattern recognition molecule, not enzyme | No catalytic site to exploit |
| Binding interfaces | Large, diffuse protein-protein interaction surfaces | Poor fit for 483 Da small molecule |
| Known binding partners | gC1qR, LAIR-1, CD93, CRP, pentraxins | All involve multivalent, high-avidity interactions |
| Structural resolution | Crystal structure (PDB: 1PKJ) available | No deep hydrophobic pockets identified |
| Druggability precedent | No small-molecule C1q inhibitors in clinic | Target considered "undruggable" by traditional standards |

Chemical Matter Assessment

Alectinib's physicochemical properties:

| Parameter | Value | Relevance |
|-----------|-------|-----------|
| MW | 483 Da | Modest size, but below typical PPI modulator threshold (>500-1000 Da) |
| cLogP | ~4.5 | High lipophilicity; enables membrane partitioning |
| PSA | ~83 Ų | Moderate polar surface |
| HBD/HBA | 2/5 | Can participate in hydrogen bonding |
| pKa | ~7.5 (piperidine) | Partially ionized at physiological pH |

Key insight: Alectinib was explicitly optimized for the ALK ATP-binding cleft. Its molecular features (2,4-difluorophenyl moiety, urea linker, morpholine) are specific to kinase hinge interactions, not general protein-binding motifs. The high selectivity (>200-fold over other kinases) argues against promiscuous off-target protein binding.

Part II: Hypothesis-by-Hypothesis Evaluation

Hypothesis 1: Cryptic Kinase-Like Pocket (Revised: 0.15)

Verdict: Structurally implausible

| Evidence Type | Weight | Assessment |
|---------------|--------|------------|
| C1q fold (PDB: 1PKJ) | Heavy | Novel trimeric β-grasp fold, no kinase homology |
| ALK selectivity data | Heavy | >200-fold selectivity profile indicates no kinase-like sites elsewhere |
| Surface residue distribution | Moderate | Aromatic residues cited are surface-exposed, not pocket-forming |

Practical experiment to falsify: Crystallize C1q globular domain with Alectinib. If no electron density appears at 2.5 Å resolution, hypothesis is refuted. This is technically feasible (C1qA structure solved), cost: ~$5,000-15,000 per crystal form.

Reactivity: Low. Pursuing this hypothesis would require demonstrating that C1q can adopt an ALK-like conformation, which has no structural or evolutionary basis.

Hypothesis 2: CRP Axis Disruption (Revised: 0.20)

Verdict: Mechanistically confused

| Claim | Correction |
|-------|------------|
| "C1qA receptor-binding interface" | CRP binds C1qC chain collagen region, not C1qA globular domain |
| "2-hydroxy-3-methoxybenzyl mimics phosphocholine" | Phosphocholine has quaternary ammonium; Alectinib has no positive charge at physiological pH |
| "IC50 < 100 nM" | CRP-C1q is multivalent; small molecules cannot competitively displace hexameric CRP |

Structural mismatch: CRP binds the collagenous region of C1q through Ca²⁺-dependent interactions. This region is sterically inaccessible to Alectinib in intact C1q hexamers.

Practical experiment: Competitive SPR with CRP. Cost: ~$2,000-5,000. If no competition at 10 μM Alectinib, hypothesis is refuted.

Hypothesis 3: Calcium-Mediated Bridging (Revised: 0.10)

Verdict: Thermodynamically impossible

| Parameter | Value | Problem |
|-----------|-------|---------|
| Phenolic-Ca²⁺ affinity | 10⁻³ to 10⁻⁴ M | Orders of magnitude weaker than "high-affinity" |
| C1q Ca²⁺ sites | Non-specific structural stabilization | No canonical EF-hand or high-affinity sites |
| Required geometry | Unfavorable | Methoxy groups are poor Ca²⁺ coordinators |

This hypothesis confuses two facts:

Neither implies that Alectinib-Ca²⁺-C1q forms a specific ternary complex.

Reactivity: Very low. The thermodynamics simply don't work.

Hypothesis 4: gC1qR/p32 Competition (Revised: 0.35)

Verdict: Mechanistically distinct, requires reframing

This is the most interesting hypothesis because it involves a known C1q receptor rather than C1q itself. However:

| Issue | Assessment |
|-------|------------|
| Primary localization | gC1qR is mitochondrial; surface expression is activation-dependent |
| Electrostatic mismatch | gC1qR binding site is basic; Alectinib is neutral/hydrophobic |
| Mechanism interpretation | "Binding to C1q" ≠ "competitive inhibition of C1q-gC1qR" |

If this mechanism operates, the claim should be reframed as: "Alectinib inhibits C1q-gC1qR signaling by binding to gC1qR," not "high-affinity binding to C1q."

Practical experiments:

| Experiment | Cost | Outcome |
|------------|------|---------|
| Purified gC1qR + Alectinib SPR | ~$3,000-8,000 | Direct binding measurement |
| C1q-gC1qR co-IP with/without Alectinib | ~$1,500-3,000 | Functional competition |
| gC1qR knockout validation | ~$5,000-10,000 | Genetic confirmation |

Reactivity: Moderate. This is worth investigating but requires abandoning the "direct C1q binding" framing.

Hypothesis 5: Metabolite Covalent Adduct (Revised: 0.15)

Verdict: Pharmacokinetically implausible

| Issue | Assessment |
|-------|------------|
| Metabolic pathway | Alectinib → M4 (N-desmethyl) is major pathway; iminium is minor |
| Circulating metabolite exposure | Reactive intermediates are detoxified by GSH in hepatocytes |
| C1q accessibility | Plasma C1q (150-200 μg/mL) not exposed to hepatic metabolites |
| Clinical safety | No complement-related autoimmune adverse events in alectinib trials |

Alectinib does form covalent adducts—but with ALK Cys1157 (the basis for its irreversible binding in some formulations). C1qA has no cysteine at an equivalent position, and the binding pocket topology is completely different.

Reactivity: Low. Requires improbable pharmacokinetic scenario.

Hypothesis 6: Membrane Lipid Raft Anchoring (Revised: 0.30)

Verdict: Mechanistically plausible for apparent affinity, not specific binding

This hypothesis correctly identifies that lipophilicity can create apparent high-affinity through membrane partitioning. However:

| Distinction | Specific Binding | Membrane Partitioning |
|-------------|------------------|----------------------|
| KD definition | Thermodynamic equilibrium constant | Includes partitioning equilibria |
| Concentration | Bulk concentration | Local membrane concentration |
| Reproducibility | Same in solution and membrane | Only observed in membrane contexts |

If this mechanism is operative, the claim should be: "Alectinib shows apparent high-affinity for membrane-associated C1q due to membrane partitioning," not "high-affinity binding to C1q."

Practical experiments:

| Experiment | Cost | Interpretation |
|------------|------|----------------|
| Solution-phase ITC (no membranes) | ~$2,000-4,000 | KD >1 μM → partitioning artifact |
| Soluble C1q globular domain SPR | ~$1,500-3,000 | KD measurement in absence of membranes |
| Lipid composition series | ~$3,000-6,000 | Specific lipids required? |

Reactivity: Moderate. This is likely the explanation for apparent high-affinity in membrane-based assays but does not constitute specific protein binding.

Hypothesis 7: LAIR-1 ITIM Cross-Reactivity (Revised: 0.20)

Verdict: Sterically and mechanistically impossible

| Issue | Assessment |
|-------|------------|
| Distance problem | C1q collagen tail extends ~200 Å; Alectinib cannot bridge this distance |
| LAIR-1 target | ITIM motifs recruit phosphatases; no kinase activity to inhibit |
| Molecular dimensions | C1q-LAIR-1 interface spans 1000+ Ų; Alectinib covers ~300 Ų |

The collagenous region of C1q contains the LAIR-1 binding site—this is the extended Gly-X-Y repeat region, not the globular heads. Alectinib would need to penetrate deep into the collagen triple helix, which is sterically impossible.

Reactivity: Very low. Geometric constraints are prohibitive.

Part III: Competitive Landscape and Tool Compounds

Existing C1q-Targeting Strategies

| Strategy | Examples | Stage | Target | Limitations |
|----------|----------|-------|--------|-------------|
| Monoclonal antibodies | IgG1 anti-C1q (numerous) | Research only | C1q directly | Large size, no BBB penetration |
| Peptide inhibitors | C1q globular domain peptides | Preclinical | gC1qR binding interface | Low potency, proteolytic liability |
| Receptor blockers | Anti-gC1qR antibodies | Research | gC1qR | Same limitations as anti-C1q |
| Complement pathway | Eculizumab, ravulizumab | Approved (other targets) | C5 | Do not target C1q directly |
| Small molecules | No direct C1q inhibitors | None in clinic | N/A | Target considered undruggable |

Relevant Tool Compounds for Comparison

| Compound | Target | Relevance | Key Feature |
|----------|--------|-----------|-------------|
| Eculizumab | C5 | Approved complement drug | Demonstrates complement can be drugged |
| Avacopan | C5aR1 | Oral small molecule | Shows oral complement inhibition possible |
| PMX-53 | C5aR1 | Peptide antagonist | Preclinical proof-of-concept |
| N-acetylphenylalanine amides | gC1qR | Research compounds | Rare C1q receptor ligands |

Critical gap: There are no selective, CNS-penetrant small molecule C1q modulators. This represents both an opportunity and a warning—the absence of precedent suggests either no one has succeeded (target is difficult) or there's no therapeutic rationale (target may not be disease-relevant).

Part IV: Safety Concerns

If Alectinib Does Bind C1q or C1q Receptors

| Risk | Severity | Clinical Precedent |
|------|----------|-------------------|
| Complement dysregulation | High | Eculizumab requires meningococcal vaccination; risk of infections |
| Classical pathway inhibition | Moderate | Would affect immune complex clearance |
| Microglial function | Unknown | Could impair host defense or cause neuroimmune dysregulation |
| Synaptic remodeling | Context-dependent | Beneficial in AD; potentially harmful in infection |

Alectinib's Known Safety Profile

| System | Adverse Events | Relevance to C1q Hypothesis |
|--------|---------------|----------------------------|
| Hepatic | Elevated LFTs | Metabolite hypothesis unlikely |
| Hematologic | Anemia, neutropenia | No complement-related cytopenias reported |
| Pulmonary | ILD/pneumonitis | Rare, mechanism unclear |
| Renal |creatinine elevation | Not complement-mediated |

Key observation: Alectinib's safety profile in >1,000 patients treated in clinical trials shows no pattern suggestive of complement activation or dysregulation. This argues strongly against a C1q-binding mechanism at therapeutic concentrations.

Part V: Cost and Timeline for Investigation

Recommended Prioritized Experiments

| Priority | Experiment | Estimated Cost | Timeline | Decision Point |
|----------|------------|----------------|----------|----------------|
| 1 | Orthogonal binding validation (ITC, AUC, MST) | $8,000-15,000 | 2-3 weeks | Reproduce Nano Letters finding |
| 2 | Solution-phase SPR with soluble C1q | $3,000-6,000 | 1-2 weeks | Membrane artifact vs. specific binding |
| 3 | Compare ALK inhibitor series (crizotinib, brigatinib, lorlatinib) | $5,000-12,000 | 3-4 weeks | Structure-activity relationship |
| 4 | C1qA mutagenesis + binding | $15,000-25,000 | 8-12 weeks | Site mapping |
| 5 | Crystallography of C1q + Alectinib | $20,000-50,000 | 6-12 months | Definitive structural evidence |

Total for basic validation: ~$15,000-30,000, 2-3 months

Full investigation if validated: ~$100,000-200,000, 12-18 months

Risk-Adjusted Assessment

| Outcome | Probability | Implication |
|---------|-------------|--------------|
| Finding is reproducible (any mechanism) | 20-30% | Worth pursuing; investigate SAR |
| Finding is membrane/avidity artifact | 50-60% | Publish negative result; explain mechanism |
| Finding is irreproducible | 20-30% | Question Nano Letters methodology |

Part VI: Revised Summary and Recommendations

Confidence Matrix

| Hypothesis | Mechanistic Plausibility | Experimental Feasibility | Recommended Investment |
|------------|-------------------------|-------------------------|------------------------|
| 1. Cryptic kinase pocket | Very Low | Moderate | $5,000 (crystallography) |
| 2. CRP axis | Low | Easy | $3,000 (competition SPR) |
| 3. Calcium bridging | Very Low | Easy | $2,000 (EDTA titration) |
| 4. gC1qR competition | Moderate | Moderate | $10,000 (gC1qR binding) |
| 5. Metabolite adduct | Low | Moderate | $8,000 (MS of adducts) |
| 6. Membrane anchoring | Moderate | Easy | $5,000 (solution ITC) |
| 7. LAIR-1 bridging | Very Low | Difficult | $0 (not worth pursuing) |

Key Recommendations

• They involve known C1q-interacting proteins
• They generate directly testable predictions
• They reframing the claim appropriately (inhibition of C1q signaling, not direct C1q binding)

Final Assessment

Pre-test probability of any hypothesis being correct: ~15-25% (assuming the Nano Letters finding is reproducible)

Post-test probability after basic validation experiments: Will be updated based on results

Bottom line: The mechanistic hypotheses range from "structurally impossible" (Hypothesis 1, 7) to "mechanistically distinct" (Hypothesis 4, 6). Before any investment in mechanism elucidation, the field requires independent reproduction of the Nano Letters finding with rigorous controls. The absence of C1q-targeted small molecules in clinical development reflects genuine druggability challenges—not a gap waiting to be filled by a repurposed kinase inhibitor.